Semaglutide

Semaglutide be antidiabetic medication dem use for de treatment of type 2 diabetes den anti-obesity medication dem use for long-term weight management.Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982. Ebe peptide similar to de hormone glucagon-like peptide-1 (GLP-1), dem modify plus side chain.Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966. Dem fi administer am by subcutaneous injection anaa dem fi take am orally.Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761."Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021."Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021."Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022. Dem dey sell am under de brand names Ozempic den Rybelsus for diabetes, den under de brand name Wegovy for weight loss.

Semaglutide be glucagon-like peptide-1 receptor agonist. De most common side effects dey include nausea, vomiting, diarrhea, abdominal pain, den constipation."Ozempic EPAR". European Medicines Agency (EMA). 8 February 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020."Rybelsus EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020."Wegovy EPAR". European Medicines Agency. 6 January 2022. Archived from the original on 2 July 2022. Retrieved 11 March 2022."Ozempic Drug Trial Snapshot". U.S. Food and Drug Administration (FDA). 5 December 2017. Archived from the original on 31 December 2023. Retrieved 31 December 2023. This article incorporates text from this source, which is in the public domain.

Na dem approve am for medical use insyd de US insyd 2017."Drug Approval Package: Ozempic (semaglutide) Injection". U.S. Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 1 March 2021. Retrieved 26 September 2020. Insyd 2022, na ebe de 48th most commonly prescribed medication insyd de United States, plus more dan 13 million prescriptions."The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024."Semaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

 References 
Category:Translated from MDWiki

 External links 
Semaglutide at Wikipedia ein sisto projects
 link=https://commons.wikimedia.org/wiki/Basshunter?uselang=gpe|16x16px Wikimedia Commons
 link=https://en.wiktionary.org/wiki/Basshunter?uselang=gpe|16x16px Wiktionary
 link=https://www.wikidata.org/wiki/Q383541|16x16px Wikidata
Scholia get profile for semaglutide (Q27261089).

 "Semaglutide tablet". MedlinePlus.
 Clinical trial number NCT03574597 for "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)" at ClinicalTrials.gov
Category:GLP-1 receptor agonists
Category:Peptide therapeutics
Category:Peptide hormones
Category:Drugs wey Novo Nordisk develop
Category:Danish inventions
Category:2008 insyd Denmark
Category:2008 insyd science